Realize safe, scalable, and compliant cell therapies by building analytical strategies that exceed regulatory expectations.

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented ...

In our best practices blog, we explore how lateral flow assay design affects test performance. Read on to gain a deeper understanding of the development process, enabling you to streamline the ...

The global pandemic has increased focus and scrutiny on molecular diagnostic assay development, resulting in a need for assays that provide quick results while delivering expected performance and ...

Joint development strategy has been developed to address international deployment requirements if current outbreak continues or expands globally ...

Allogene Therapeutics has announced an expanded collaboration with Foresight Diagnostics to develop a minimal residual disease (MRD) assay as a companion diagnostic tool for identifying patients with ...

Since biological therapeutics are derived from living organisms, their manufacture and validation presents difficulties not encountered during traditional small molecule drug development. Despite the ...

A good bioassay, like a good marriage, joins two partners in a bond and is mutually beneficial. In the case of bioassays, optimal design and development and accurate statistical analysis comprise a ...

Cancer research increasingly depends on assays that can keep pace with biological complexity, interrogating key mechanisms such as signaling pathways, enzyme activity, and cell metabolism. 1,2 As ...

This article and associated images are based on a poster originally authored by Linda Kitching, Maxime Couturier, Jonathan Tart, Erik Elebring, Marcel Taillefer, Claudio Pathe, Giulia Bonetto, ...

As AI accelerates target discovery and pushes more candidates toward the bench, assay development and transfer have become critical bottlenecks. Teams relying on one-factor-at-a-time (OFAT) workflows ...